Nasdaq · Healthcare
GYRE THERAPEUTICS, INC. (GYRE)
As-reported financials and recent SEC filings for GYRE THERAPEUTICS, INC., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$116.6M
Net income
$9.9M
Net margin
8.5%
Diluted EPS
$0.02
ROE
6.9%
P/E (TTM)
—
Market cap
—
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $116.6M | $105.8M | $113.5M | $102.3M | $7.3M |
| Gross profit | — | — | — | — | — |
| Operating income | $11.5M | $16.2M | $-67.2M | $9.2M | $-87.9M |
| Net income | $9.9M | $17.9M | $-85.5M | $4.3M | $-87.9M |
| Diluted EPS | $0.02 | $0.05 | $-1.41 | $0.03 | $-1.44 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-30
View on EDGAR →42026-06-30
View on EDGAR →42026-06-30
View on EDGAR →42026-06-30
View on EDGAR →42026-06-30
View on EDGAR →42026-06-30
View on EDGAR →S-32026-06-23
View on EDGAR →42026-06-22
View on EDGAR →Largest Healthcare peers
Go deeper on GYRE
Search GYRE THERAPEUTICS, INC.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.